SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Roger's 1998 Short Picks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wendell morris who wrote (2051)2/1/1998 9:56:00 AM
From: clochard  Read Replies (1) of 18691
 
Better look again. The company has had good results from its Phase III trial of ziconotide (SNX-111) to treat neuropathic pain. NXCO noted that it plans to submit a New Drug Application with the Food and Drug Administration. The stock was upgraded by Morgan Stanley recently.

If you want to contribute to this thread, you should do some research first. The information above came from a simple yahoo quote.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News